Search Results

50 results

  1. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 25

    Misperception of e-cigarette harm growing among American adults, 2013-2015

    VERRON T.(1); GUO M.(1); VARIGNON B.(1); O'CONNELL G.(2); WALELE T.(2); CAHOURS X.(1)
    (1) SEITA - Imperial Brands plc, Paris, France; (2) Fontem Ventures B.V., Amsterdam, The Netherlands
    Electronic cigarettes (e cigarettes) have been characterised as significantly less harmful than smoked tobacco by an increasing number of public health authorities. However, the proportion of American adults who perceive e cigarettes to be equally or more ...
  2. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 35

    Different population modeling approaches lead to directionally similar conclusions about the potential for tobacco harm reduction

    BACHAND A.(1); SULSKY S.(1); CURTIN G.(2)
    (1) Ramboll U.S. Corp., Amherst, MA, U.S.A.; (2) RAI Services Co., Winston-Salem, NC, U.S.A.
    There are a number of dynamic population models that can be used to quantify the overall population health effects of beneficial and/or harmful changes in tobacco use patterns. These models can be broadly categorized as either following a single birth ...
  3. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 36 (also presented at TSRC 2018)

    Multi-dimensional tipping point analyses: Assessing simultaneous shifts in tobacco use patterns from a higher to a lower risk product

    BACHAND A.(1); SULSKY S.(1); CURTIN G.(2)
    (1) Ramboll U.S. Corp., Amherst, MA, U.S.A.; (2) RAI Services Co., Winston-Salem, NC, U.S.A.
    The Dynamic Population Modeler (DPM(+1)) employs a birth cohort framework to estimate effects on population mortality if tobacco use patterns shift from a higher- to lower-risk product. DPM(+1) allows for evaluation of changes in use patterns within the ...
  4. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 52

    Biological test procedure for fresh generated cigarette smoke and e-cigarette aerosols under air-liquid interface (ALI) exposure in 24 and 96 multi-well plates

    WIECZOREK R.(1); TRELLES STICKEN E.(1); WALELE T.(2); CZEKALA L.(3); SIMMS L.(3)
    (1) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (2) Fontem Ventures, Amsterdam, The Netherlands; (3) Imperial Tobacco Limited, Bristol, U.K.
    Cigarette smoke and e cigarette aerosol contain particulate matter/liquid droplets in the solid phase as well as volatile substances in the gas phase. Both fractions are of potential toxicological relevance and should be considered when assessing ...
  5. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 53

    Use of human derived cell lines to increase the biological relevance of cigarette condensate, non-tobacco materials and e-liquids testing

    WIECZOREK R.(1); TRELLES STICKEN E.(1); WALELE T.(2); CZEKALA L.(3); SIMMS L.(3)
    (1) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (2) Fontem Ventures, Amsterdam, The Netherlands; (3) Imperial Tobacco Limited, Bristol, U.K.
    The in vitro testing strategy of tobacco products is mainly based on the testing of extracts from cigarette smoke condensates. An accepted industry wide assay battery has been developed over recent years which delivers reliable results for the ...
  6. TSRC, Tob. Sci. Res. Conf., 2018, 72, abstr. 037 (also presented at CORESTA 2018)

    Multi-dimensional tipping point analyses: assessing simultaneous shifts in tobacco use patterns from a higher to a lower risk product

    CURTIN G.M.(1); BACHAND A.(2); SULSKY S.(2)
    (1) RAI Services Company, Winston-Salem, NC, USA; (2) Ramboll US Corporation, Amherst, MA, USA
    The Dynamic Population Modeler (DPM(+1)) employs a birth cohort framework to estimate effects on population mortality if tobacco use patterns shift from a higher- to lower-risk product. DPM(+1) allows for evaluation of changes in use patterns within the ...
  7. TSRC, Tob. Sci. Res. Conf., 2018, 72, abstr. 076

    Do levels of menthol in mainstream cigarette smoke influence dependence? Data from NHANES 2007-2014

    PARMS T.(1); VAN LANDINGHAM C.(2); MARANO K.M.(1)
    (1) RAI Services Company, Winston-Salem, NC, USA; (2) Ramboll, Monroe, LA, USA
    A 2013 preliminary scientific evaluation by the U.S. Food and Drug Administration (FDA) concluded that menthol in cigarettes is likely associated with increased initiation and progression to regular cigarette smoking, increased dependence, and reduced ...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 38

    Assessing the likelihood and magnitude of a population health benefit following market introduction of a modified risk tobacco product (MRTP)

    CURTIN G.(1); SULSKY S.(2); BACHAND A.(2)
    (1) RAI Services Co., Winston-Salem, NC, U.S.A.; (2) Ramboll Environ US Corp., Amherst, MA, U.S.A.
    The evaluation and implementation of tobacco policies intended to reduce harm to the population as a whole, including tobacco users and non-users, must assess the potential for both intended and unintended consequences associated with those policies. ...
  9. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 39

    Addressing U.S. FDA’s population health standard for Camel Snus with modified risk messaging

    CURTIN G.(1); BACHAND A.(2); SULSKY S.(2); GERLACH K.(3); PILLITTERI J.(4); SHIFFMAN S.(3)
    (1) RAI Services Co., Winston-Salem, NC, U.S.A.; (2) Ramboll Environ US Corp., Amherst, MA, U.S.A.; (3) Pinney Associates, Inc., Pittsburgh, PA, U.S.A.; (4) Pinney Associates, Inc., Burlington, VT, U.S.A.
    R.J. Reynolds Tobacco Company has submitted Modified Risk Tobacco Product applications to the U.S. Food and Drug Administration seeking risk modification orders for Camel Snus advertising, which includes information that smokers who switch completely to ...
  10. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 40

    FDA’s proposed NNN product standard: review of the scientific evidence

    MARANO K.M.(1); BACHAND A.(2); LIU C.(1); SULSKY S.(2); MARIANO G.(2); CURTIN G.M.(1); PARMS T.(1); GREEN T.(3); GENTRY P.R.(3)
    (1) RAI Services Co., Winston-Salem, NC, U.S.A.; (2) Ramboll Environ US Corp., Amherst, MA, U.S.A.; (3) Ramboll Environ, Monroe, LA, U.S.A.
    The U.S. Food and Drug Administration (FDA) has published a proposed standard of 1 µg/g (dry weight) N-nitrosonornicotine (NNN) in finished smokeless tobacco products. FDA’s rationale for the standard is that NNN is a potent carcinogen, NNN is a major ...